|
Peposertib Clinical Trials
6 actively recruiting trials across 4 locations
Also known as: 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A +3 more
Pipeline
Phase 1: 3Phase 1/2: 3
Top Sponsors
- National Cancer Institute (NCI)4
- M.D. Anderson Cancer Center1
- Gustave Roussy, Cancer Campus, Grand Paris1
Indications
- Cancer6
- Metastatic Malignant Neoplasm in the Lymph Nodes1
- Metastatic Castration-Resistant Prostate Carcinoma1
- Locally Advanced Pancreatic Adenocarcinoma1
- Metastatic Malignant Neoplasm in the Bone1
Duarte, California2 trials
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
City of Hope Comprehensive Cancer Center
Phase 1/2
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
City of Hope Comprehensive Cancer Center
Phase 1/2
Other1 trial
Los Angeles, California1 trial
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Los Angeles General Medical Center
Phase 1
Bethesda, Maryland1 trial
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute Developmental Therapeutics Clinic
Phase 1
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.